Cardiovascular risk profile with the new immunosuppressive combinations after renal transplantation

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Cardiovascular disease (CVD) is the leading cause of mortality in kidney transplant recipients.
• Immunosuppressive medications, essential for graft survival, can exacerbate pre-existing cardiovascular risk factors.
• Chronic allograft nephropathy (CAN) is the primary cause of long-term graft loss, with non-immunological factors, including CVD risk factors, contributing to its development.

Purpose of the Study:

• To review the impact of various immunosuppressive drugs on cardiovascular risk factors after renal transplantation.
• To assess the influence of these medications on renal function in transplant patients.

Main Methods:

• Literature review of studies investigating immunosuppressants, cardiovascular risk factors, and renal function post-kidney transplantation.
• Analysis of the interplay between non-immunological factors, cardiovascular risk, and chronic allograft nephropathy.

Main Results:

• Immunosuppressants significantly affect lipid profiles, blood pressure, and glucose metabolism, thereby increasing cardiovascular risk.
• Certain immunosuppressive regimens are associated with a higher burden of cardiovascular risk factors.
• The impact on renal function varies among different immunosuppressive agents.

Conclusions:

• Careful selection and monitoring of immunosuppressive therapy are crucial to mitigate cardiovascular risk in kidney transplant recipients.
• Managing cardiovascular risk factors is essential for improving long-term outcomes and graft survival.
• Further research is needed to optimize immunosuppression strategies for reducing both cardiovascular morbidity and chronic allograft nephropathy.